<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000792</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 258</org_study_id>
    <secondary_id>11235</secondary_id>
    <nct_id>NCT00000792</nct_id>
  </id_info>
  <brief_title>A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects</brief_title>
  <official_title>A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VIMRx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerance of daily oral hypericin when given to achieve target&#xD;
      trough levels within defined cohorts. To determine the responses of surrogate markers of HIV&#xD;
      infection to daily oral hypericin.&#xD;
&#xD;
      It is not known whether daily oral dosing will produce a tolerable prolonged exposure to&#xD;
      therapeutic levels of hypericin. Pharmacokinetic modeling studies have demonstrated that&#xD;
      daily oral dosing should produce a trough level in a desired range without excessive peak&#xD;
      levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is not known whether daily oral dosing will produce a tolerable prolonged exposure to&#xD;
      therapeutic levels of hypericin. Pharmacokinetic modeling studies have demonstrated that&#xD;
      daily oral dosing should produce a trough level in a desired range without excessive peak&#xD;
      levels.&#xD;
&#xD;
      Cohorts of six patients each receive escalating doses of oral hypericin daily. Blood is&#xD;
      sampled for peak and trough levels the second week of therapy. A computer modeling algorithm&#xD;
      will use these levels to determine the appropriate dose needed for each patient to achieve&#xD;
      the desired trough level. When three of six patients at a given dose have completed 3 weeks&#xD;
      of therapy without evidence of dose-limiting toxicity, data will be reviewed to determine&#xD;
      whether subsequent patients should be entered at the next higher dose. The MTD is defined as&#xD;
      the dose level immediately below that at which grade 3 or worse toxicity is seen in three or&#xD;
      more of six patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">January 1995</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypericin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  PCP prophylaxis.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Rifabutin, ketoconazole, fluconazole, and acyclovir, provided the medication has been&#xD;
             taken for at least 4 weeks prior to study entry without toxicity.&#xD;
&#xD;
          -  Topical medications such as clotrimazole troches or nystatin suspension.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 count &lt;= 350 cells/mm3.&#xD;
&#xD;
          -  p24 antigen positive at &gt;= 35 pcg/ml.&#xD;
&#xD;
          -  No active opportunistic infection at study entry that would require curative or&#xD;
             suppressive therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy for which systemic chemotherapy is required.&#xD;
&#xD;
          -  Medically significant liver disease, orthostatic hypotension, hypertension, cardiac&#xD;
             disease, seizure disorders, or lymphoma.&#xD;
&#xD;
          -  Any medical condition that would interfere with evaluation of the patient.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  AZT, ddI, ddC, d4T, or any other antiretroviral medication.&#xD;
&#xD;
          -  Interferon or other immunomodulating drugs.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Antimycobacterial drugs other than rifabutin.&#xD;
&#xD;
          -  MAO inhibitors.&#xD;
&#xD;
          -  Hypertension-inducing, nephrotoxic, or hepatotoxic drugs.&#xD;
&#xD;
          -  Opiates.&#xD;
&#xD;
          -  Drugs known to cause photosensitivity.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 1 month prior to study entry:&#xD;
&#xD;
          -  AZT, ddI, ddC, d4T, or any other antiretroviral medication.&#xD;
&#xD;
          -  Interferon or other immunomodulating drugs.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Preparations known to contain hypericin.&#xD;
&#xD;
        Excluded within 3 months prior to study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Hyperforate (500 mg tablets or ampules for IV injection) manufactured by Kline.&#xD;
&#xD;
          -  Psychotonin M Alcohol Extract manufactured by Steigerwald.&#xD;
&#xD;
          -  Hypericin (40 mg vial) by VIMRx.&#xD;
&#xD;
        Excluded within 14 days prior to study entry:&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Antimycobacterial drugs other than rifabutin.&#xD;
&#xD;
          -  MAO inhibitors.&#xD;
&#xD;
          -  Hypertension-inducing, nephrotoxic, or hepatotoxic drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentine FT</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Crumpacker C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - East Campus A0102 CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Furner V, Bek M, Gold J. A Phase I/II unblinded dose ranging study of hypericin in HIV-positive subjects. Int Conf AIDS. 1991 Jun 16-21;7(2):199 (abstract no WB2071)</citation>
  </reference>
  <reference>
    <citation>Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med. 1999 Mar 16;130(6):510-4. doi: 10.7326/0003-4819-130-6-199903160-00015.</citation>
    <PMID>10075619</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypericin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

